Literature DB >> 33719224

Traditional Chinese medicines and their active ingredients sensitize cancer cells to TRAIL-induced apoptosis.

Bingyu Sun1,2, Yongqiang Liu3, Danhua He3, Jinke Li4, Jiawei Wang5, Wulin Wen6, Ming Hong7,8.   

Abstract

The rapidly developing resistance of cancers to chemotherapy agents and the severe cytotoxicity of such agents to normal cells are major stumbling blocks in current cancer treatments. Most current chemotherapy agents have significant cytotoxicity, which leads to devastating adverse effects and results in a substandard quality of life, including increased daily morbidity and premature mortality. The death receptor of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can sidestep p53-dependent pathways to induce tumor cell apoptosis without damaging most normal cells. However, various cancer cells can develop resistance to TRAIL-induced apoptosis via different pathways. Therefore, it is critical to find an efficient TRAIL sensitizer to reverse the resistance of tumor cells to TRAIL, and to reinforce TRAIL's ability to induce tumor cell apoptosis. In recent years, traditional Chinese medicines and their active ingredients have shown great potential to trigger apoptotic cell death in TRAIL-resistant cancer cell lines. This review aims to collate information about Chinese medicines that can effectively reverse the resistance of tumor cells to TRAIL and enhance TRAIL's ability to induce apoptosis. We explore the therapeutic potential of TRAIL and provide new ideas for the development of TRAIL therapy and the generation of new anti-cancer drugs for human cancer treatment. This study involved an extensive review of studies obtained from literature searches of electronic databases such as Google Scholar and PubMed. "TRAIL sensitize" and "Chinese medicine" were the search keywords. We then isolated newly published studies on the mechanisms of TRAIL-induced apoptosis. The name of each plant was validated using certified databases such as The Plant List. This study indicates that TRAIL can be combined with different Chinese medicine components through intrinsic or extrinsic pathways to promote cancer cell apoptosis. It also demonstrates that the active ingredients of traditional Chinese medicines enhance the sensitivity of cancer cells to TRAIL-mediated apoptosis. This provides useful information regarding traditional Chinese medicine treatment, the development of TRAIL-based therapies, and the treatment of cancer.

Entities:  

Keywords:  Apoptosis; Cancer therapy; Chinese medicine; Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)

Year:  2021        PMID: 33719224      PMCID: PMC7982325          DOI: 10.1631/jzus.B2000497

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  100 in total

1.  Ginseng intestinal bacterial metabolite IH901 as a new anti-metastatic agent.

Authors:  H Hasegawa; J H Sung; J H Huh
Journal:  Arch Pharm Res       Date:  1997-12       Impact factor: 4.946

2.  CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells.

Authors:  A Trauzold; H Wermann; A Arlt; S Schütze; H Schäfer; S Oestern; C Röder; H Ungefroren; E Lampe; M Heinrich; H Walczak; H Kalthoff
Journal:  Oncogene       Date:  2001-07-12       Impact factor: 9.867

3.  Inhibition of p38 mitogen-activated protein kinase potentiates the apoptotic effect of berberine/tumor necrosis factor-related apoptosis-inducing ligand combination therapy.

Authors:  Alaa Refaat; Sherif Abdelhamed; Ikuo Saiki; Hiroaki Sakurai
Journal:  Oncol Lett       Date:  2015-07-15       Impact factor: 2.967

4.  Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels.

Authors:  Asli Kisim; Harika Atmaca; Burcu Cakar; Bulent Karabulut; Canfeza Sezgin; Selim Uzunoglu; Ruchan Uslu; Burcak Karaca
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-13       Impact factor: 4.553

5.  Phytoestrogens derived from Belamcanda chinensis have an antiproliferative effect on prostate cancer cells in vitro.

Authors:  Colm Morrissey; Jasmin Bektic; Barbara Spengler; David Galvin; Volker Christoffel; Helmut Klocker; John M Fitzpatrick; R William G Watson
Journal:  J Urol       Date:  2004-12       Impact factor: 7.450

6.  Bakuchiol sensitizes cancer cells to TRAIL through ROS- and JNK-mediated upregulation of death receptors and downregulation of survival proteins.

Authors:  Mi Hee Park; Jong Han Kim; Young-Ho Chung; Seung Ho Lee
Journal:  Biochem Biophys Res Commun       Date:  2016-03-28       Impact factor: 3.575

7.  Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway.

Authors:  Zhiyu Chen; Veena Sangwan; Sulagna Banerjee; Rohit Chugh; Vikas Dudeja; Selwyn M Vickers; Ashok K Saluja
Journal:  Cancer Lett       Date:  2014-03-21       Impact factor: 8.679

8.  Andrographolide sensitizes prostate cancer cells to TRAIL-induced apoptosis.

Authors:  Ruo-Jing Wei; Xin-Shi Zhang; Da-Lin He
Journal:  Asian J Androl       Date:  2018 Mar-Apr       Impact factor: 3.285

9.  Shikonin inhibits the proliferation of human lens epithelial cells by inducing apoptosis through ROS and caspase-dependent pathway.

Authors:  Wan-Rong Huang; Yue Zhang; Xin Tang
Journal:  Molecules       Date:  2014-06-11       Impact factor: 4.411

10.  TRAIL and curcumin codelivery nanoparticles enhance TRAIL-induced apoptosis through upregulation of death receptors.

Authors:  Xi Yang; Zhaojun Li; Qinjie Wu; Shouchun Chen; Cheng Yi; Changyang Gong
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

View more
  1 in total

Review 1.  Autophagy and cancer treatment: four functional forms of autophagy and their therapeutic applications.

Authors:  Zhaoshi Bai; Yaling Peng; Xinyue Ye; Zhixian Liu; Yupeng Li; Lingman Ma
Journal:  J Zhejiang Univ Sci B       Date:  2022-02-15       Impact factor: 3.066

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.